Yabin Liu

Prof. Dr. Yabin Liu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWen-Di Zhang
Wen-Di Zhang
DZDan-Dan Zhang
Dan-Dan Zhang
XWXu Wang
Xu Wang
CLChen-Yang Li
Chen-Yang Li
FLFan-Qin Li
Fan-Qin Li
MHMei Han
Mei Han
Colonic smooth muscle cell (CSMC) hypertrophy and hyperplasia have been described in both human ulcerative colitis (UC) and animal models. The deletion of smooth muscle (SM) 22α induces the phenotypic switching of SMCs. Here, we report that Sm22α-deficient mice develop spontaneous colitis, which is characterized by radical S-adenosyl-methionine domain-containing 2 (RSAD2)-driven mitochondrial dysfunction and inflammation in CSMCs and ferroptosis in the colonic mucosa. Mechanistically, RSAD2 mediates YTH m6A RNA-binding protein 1 (YTHDF1) methylation and activation, thereby increasing the mRNA N6-methyladenosine (m6A) modification and translation of dynamin-related protein 1 (DRP1), resulting in mitochondrial fragmentation in CSMCs. Inflammatory CSMC-derived mitochondrial extracellular vesicles trigger intestinal epithelial ferroptosis by inducing ROS production. The ablation of RSAD2 in mice with SMC-specific Sm22α knockout alleviates colitis severity in this experimental model. Importantly, increases in both RSAD2 expression and the ferroptotic signature are observed in serum and/or colonic samples from UC patients. Overall, this study shows a mitochondrial mechanism underlying the ability of dysfunctional smooth muscle to drive colitis and highlights the potential of targeting the RSAD2-YTHDF1 axis as an innovative therapeutic strategy for colitis.

21 January 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MJMei Jia
Mei Jia
DKDexian Kong
Dexian Kong
JFJiaxu Fan
Jiaxu Fan
BHBingqian Heng
Bingqian Heng
JZJian Zhao
Jian Zhao
YLYabin Liu
Yabin Liu
Introduction: Colorectal cancer (CRC) remains one of the most lethal malignancies globally. Chemoresistance or reduced chemosensitivity is a key factor contributing to treatment failure in CRC, particularly in patients with advanced-stage disease. Iroquois homeobox protein 4 (IRX4), a transcription factor expressed in multiple tissues, has been demonstrated to be implicated in the progression of many cancers. Based on this background, IRX4 identified through Illumina Infinium 935K methylation chip analysis was chosen to explore its potential role in CRC. Methods: Following initial screening via the Illumina Infinium 935K methylation chip, we further confirmed the hypermethylation of IRX4 in CRC tissues using pyrosequencing technology. The expression levels of IRX4 were determined by immunofluorescence (IF) staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot (WB) assays. In vitro cell experiments evaluated the effects of IRX4 overexpression on the proliferation, invasion, migration, and apoptosis of CRC cells, as well as its impact on the chemosensitivity to oxaliplatin (OXA). Mechanistically, after IRX4 overexpression, the phosphorylation level of epidermal growth factor receptor (EGFR) in CRC cells was detected. Luciferase reporter gene assays and immunofluorescence staining were used to investigate the effects of IRX4 overexpression on the activation of the nuclear factor-κB (NF-κB) pathway and the nuclear translocation of the p65 subunit. Results: IRX4 was downregulated in CRC tissues and cell lines, and its expression was negatively correlated with tumor invasion depth and poor prognosis. In vitro experiments demonstrated that the overexpression of IRX4 inhibited CRC cell proliferation, migration, and invasion and promoted apoptosis. Moreover, IRX4 overexpression enhanced the chemosensitivity of CRC cells to OXA. Mechanistically, IRX4 overexpression significantly inhibited the TNF-α-induced NF-κB transcriptional activity and suppressed the nuclear translocation of NF-κB p65 in CRC cells. Furthermore, combined treatment with OXA and IRX4 overexpression significantly reduced the levels of EGFR and the phosphorylationlevels of EGFR downstream signaling molecules. Conclusion: These findings suggest that IRX4 may be a prognostic biomarker and therapeutic target in CRC. Moreover, IRX4 might regulate CRC progression and chemosensitivity by inhibiting the NF-κB /EGFR pathway, suggesting its potential as a therapeutic target to improve chemotherapeutic efficacy in CRC.

22 October 2026 in Biology Direct
Verified
Journal Article
Open access
PDF file
ZJZhen Jia
Zhen Jia
XLXinlong Liu
Xinlong Liu
LZLi Zhao
Li Zhao
HWHanbing Wang
Hanbing Wang
YLYihang Liu
Yihang Liu
DKDexian Kong
Dexian Kong
Hexokinase 2 (HK2), a key enzyme in the Warburg effect, is associated with poor prognosis in colorectal cancer (CRC). HK2 is known to exert glycolysis-inde